Correlation of SIDT1 with Poor Prognosis and Immune Infiltration in Patients with Non-Small Cell Lung Cancer

Figures & data

Table 1 Clinicopathologic Features of 140 Patients with Non-Small Cell Lung Cancer

Patient Characteristic	Number of Patients	% of Total
Age (years)
≤60	66	47
>60	74	53
Genders
Male	112	80
Female	28	20
Location
Left	64	46
Right	76	54
Pathologic type
Squamous cell carcinoma	80	57
Adenocarcinoma	46	33
Adenosquamous cell carcinoma	5	4
Bronchiolo-alveolar carcinoma	3	2
Sarcomatoid carcinoma	1	1
Neuroendocrine carcinoma	3	2
Mucoepidermoid carcinoma	2	1
Differentiation
Moderate and well	81	58
Poorly	59	42
T stage
1	12	11
2–3	125	89
N stage
0	82	59
1–2	58	41
NSCLC stage
I	67	48
II-III	73	52

Abbreviations: NSCLC, non-small cell lung cancer; T, tumor, N, node.

Figure 1 Expression of SIDT1 in tumor tissues and para-tumor tissues. In 60 pairs of tissues, SIDT1 was more highly expressed in tumor tissues than in para-tumor tissues, and the mean score of lung cancer tissues was 1.95-fold higher than normal lung tissues (A) no staining, (B) Para-tumor tissues, (C) Weak staining,(D) Moderate staining, (E) Strong staining, (F) SIDT1 was mainly expressed in the cell membrane and cytoplasm of tumor cells. Magnification, x200. ****P value < 0.001.

Figure 2 Immunohistochemical staining images of SIDT1 in NSCLC and adjacent lung tissues. In the quantitative score of SIDT1 immunohistochemistry (A) adjacent lung tissues, (B) breast cancer, (C) LUAD, (D) LUSC, (E) SIDT1 expression was higher in tumor cells than in normal adjacent lung tissues. Magnification, x200.

Abbreviations: SIDT1, systemic RNA interference-deficient-1 transmembrane family member 1; NSCLC, non-small cell lung cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.

Table 2 The Correlation Between SIDT1 Expression and Clinicopathologic Features in Patients with NSCLC

Patient Characteristic	Low	High	p value
Age (years)			0.058
≤60	23	38
>60	38	32
Genders			0.055
Male	44	60
Female	17	10
Location			0.166
Left	24	36
Right	37	34
Pathologic type			0.788
LUSC	38	42
LUAD	23	28
Differentiation			0.909
Moderate and well	36	42
Pooly	25	28
T stage			0.577
1	8	7
2–3	53	63
N stage			0.067
0	41	36
1–2	20	34
NSCLC stage			0.047*
I	35	28
II-III	26	42

Note: *Significant correlation.

Abbreviations: LUAD, lung adenocarcinoma, including bronchiolo-alveolar carcinoma and mucoepidermoid carcinoma; LUSC, Squamous cell carcinoma; NSCLC, non-small cell lung cancer; SIDT1, Systemic RNA interference-defective-1 transmembrane family member 1; TNM, Tumor-Node-Metastasis.

Table 3 Multivariate Cox Regression Analysis for Potential Factors Influencing Overall Survival in LUAD

Univariate Analysis	B	SE	Wald	P-value	Exp(B)	95% CI for Exp(B)
						Lower	Upper
Age (⩽60 vs >60)	0.514	0.287	3.207	0.073	1.672	0.953	2.935
Genders (male vs female)	−0.123	0.384	0.103	0.749	0.884	0.417	1.877
Location (left vs right)	−0.348	0.276	1.587	0.208	0.706	0.411	1.213
Differentiation (poorly vs moderate vs well)	0.227	0.281	0.653	0.419	1.255	0.723	2.178
T stage (T2-3 vs T1)	1.889	1.010	3.495	0.062	6.612	0.913	47.900
N stage (N1-2 vs N0)	0.919	0.279	10.805	0.001*	2.506	1.449	4.334
NSCLC stage (II-III vs I)	0.669	0.288	5.408	0.020*	1.953	1.111	3.433
SIDT1 expression (high vs low)	0.688	0.283	5.918	0.015*	1.990	1.143	3.465
Multivariate analysis
Age (⩽60 vs >60)	0.444	0.311	2.041	0.153	1.559	0.848	2.868
Genders (male vs female)	−0.060	0.439	0.018	0.892	0.942	0.398	2.229
Location (left vs right)	−0.072	0.297	0.058	0.809	0.931	0.520	1.666
Differentiation (poorly vs moderate vs well)	0.309	0.291	1.126	0.289	1.362	0.770	2.409
T stage (T2-3 vs T1)	1.346	1.045	1.659	0.198	3.842	0.496	29.787
N stage (N1-2 vs N0)	0.947	0.494	3.678	0.055	2.579	0.979	6.791
NSCLC stage (II-III vs I)	−0.333	0.515	0.419	0.517	0.716	0.261	1.966
SIDT1 expression (high vs low)	0.621	0.302	4.238	0.040*	1.861	1.030	3.363

Note: *Significant correlation.

Abbreviations: B, regression coefficient; SE, standard error; Wald, Wald test; Exp(B), the exponent of B; p, pathological; T, tumor; N, node; CI, confidence interval; SIDT1, Systemic RNA interference-defective-1 transmembrane family member 1.

Figure 3 Survival curves for Kaplan-Meier survival analysis of overall survival by SIDT1 expression. High expression of SIDT1 is associated with poorer prognosis in NSCLC patients (A) especially in stage I patients, (B) LUAD, (C) and LUSC, (D).

Abbreviations: SIDT1, systemic RNA interference-deficient-1 transmembrane family member 1; NSCLC, non-small cell lung cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.

Figure 4 (A) Correlation between 22 immune cells. (B) Violin plot showing the difference in 22 immune cell distributions between the high and low SIDT1-expressing groups in the cohort. ***P value < 0.001, ns means no significant difference.

Figure 5 (A) Correlation of SIDT1 expression levels with B cells, CD8T cells, CD4T cells, macrophages, neutrophils and dendritic cells in NSCLC. (B) Cumulative survival rates of B cells, CD8T cells, CD4T cells, macrophages, neutrophils and dendritic cells in NSCLC.

Figure 6 (A–C) Enrichment analysis of co-expressed genes. (D–I) GSEA results show differential enrichment between high SIDT1 expression and low SIDT1 expression.

Figure 7 (A) Line graph of NSCLC prognostic model. (B–D) NSCLC prognostic model 1-year and 3-year 5-year calibration curves.